Founded in 2008, Oneness Biotech (TPEx: 4743) is a leading biotechnology company based in Taipei, Taiwan, specializing in the development of innovative therapeutics for chronic dermatological and immunological disorders. The company went public in 2011 and has since progressed to a commercial-stage biotech firm. Its lead product is scheduled for global commercialization in 2024.
Oneness continues to conduct non-clinical and clinical trials for the global unmet medical need in compliance with the international regulations. This ensures the effectiveness, safety and consistency of the drugs, and develops drugs with the advantages in market exclusivity. Our business philosophy is to meet the medical needs of patients and create business value. We drive the new drugs into the global market by establishing global collaboration and alliance in order to facilitate the planning for the global market as well as to maximize the business value.
Date of Publication: August 2024
Period: Jan. 01, 2023 to Dec. 31, 2023
Thank you for reading the ESG Report issued by Oneness Biotech Co., Ltd. (hereinafter referred to as Oneness Biotech). By taking the initiative of issuing the ESG report, Oneness Biotech hopes to explain to the employees, customers, investors, and other stakeholders the efforts it has devoted to and the results it has achieved in terms of ethical management, new drug R&D, business performance, employee welfare, environment protection, and many other aspects under the goal of corporate sustainability. We hope that the stakeholders can continue to follow us and provide us with valuable advice so that we can continue to proceed steadily on the path of corporate sustainability.
(Date of next publication: August 2025)
